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radiotherapy (50.2Gy/27#, 50Gy/25# or 45Gy/25#) followed 
by brachytherapy (26Gy/4# or 28Gy/4# to HRCTV). In the 
current study the original treatment plans were re-optimised, 
using Brachyvision Version 11. The aim was to escalate the 
GTV(BT) dose to 140% of the original HRCTV prescription dose 
(8.4Gy and 9.8Gy/# respectively), keeping the HRCTV 
coverage and organ at risk DVH values within the tolerance 
which had been accepted for the original clinical plans. GTV 
(BT) and HRCTV were drawn according to GEC-ESTRO 
recommendations. The relationship between the volumes can 
be defined by the following equation. HRCTV2 = HRCTV1 – 
GTV(BT) The quality of the re-optimised plans was quantified 
by using dose volume histogram parameters. 
 
Results: Table 1 shows a comparison of the original and the 
re-optimised plan parameters.In 10 out of the 14 cases 
(71.4%) more than 90% of the GTV(BT) was covered by the 
140% isodose after re-optimisation.The HRCTV1 V100% was 
reduced for the re-optimised plans by an average of 2.95% 
(range 0.7-6.01%).Average coverage of HRCTV2 with the 
prescription isodose was 94.5% for the 6Gy plans, and 81.7% 
for the 7Gy plans.In 12 out of the 14 cases (85.7%) the 
treatment time was reduced with the boost plan.  
 
Conclusion: It is possible to boost the prescription dose to 
the GTV(BT) to 140% for treatment plans with interstitial 
catheters and IU within the GTV(BT) volume. Plans without 
both interstitial catheters and IU in the GTV(BT) are most 
likely to be suboptimal. This planning study demonstrates 
that dose escalation to the GTV(BT) is feasible if clinically 
indicated, and further work into clinical application and 
outcome should be considered. 
 
PO-0958  
Locally advanced cervical cancer treated with IGABT: 
impact of the D90 HR-CTV on patterns of relapse 
C. Chargari
1Institut Gustave Roussy, brachytherapy, Villejuif, France 
1, R. Mazeron1, P. Maroun1, I. Dumas1, F. 
Martinetti1, A. Tafo-Guemnie1, E. Deutsch2, P. Morice3, C. 
Haie-Meder1 
2Institut Gustave Roussy, Radiotherapy, Villejuif, France 
3Institut Gustave Roussy, Surgical Oncology, Villejuif, France 
 
Purpose or Objective: Locally advanced cervical cancer 
patients with a bulky high-risk clinical target volume (HR-
CTV) get the largest benefit of dose escalation in terms of 
local control. But the expected survival benefit could be 
lessened by a higher metastatic risk. We examined the 
patterns of relapse according to the HR-CTV and to the 
ability to reach the target dose. 
 
Material and Methods: Pts treated with chemoradiation 
between 04/2007 and 02/2012 were included if they had a 
disease limited to the pelvis after an exhaustive primary 
staging (PET/CT plus primary laparoscopic para-aortic 
lymphadenectomy) and if they had received concurrent 
chemotherapy. Pts received pelvic irradiation (45 Gy) then a 
PDR brachytherapy boost +/- a pelvic sequential boost for 
PET positive pelvic lymph nodes. First sites of relapse were 
examined. 
 
Results: 109 pts were included, with median follow-up of 39 
months. Median D90 HR-CTV was 73.5 Gy in case of HR-CTV ≥ 
30 cm3 (n = 28) versus 86.4 Gy in case of HR-CTV < 30 cm3 (p 
< 0.001). Pts with a not-bulky HR-CTV (< 30 cm3) experienced 
local failure in 5/81 (6.2%), versus in 6/28 (21.4 %) in case of 
bulky HR-CTV (p =0.03), but the HR-CTV volume did not 
correlate with the risk of local failures as only events. Pts 
with a bulky HR-CTV volume had a higher risk of distant 
failures: 10/28 (35.8 %) versus 7/81 (8.6 %) in case of not-
bulky HR-CTV (p = 0.002). Local failures were seen in 3/47 
(6.4 %) for pts with a D90 HR-CTV ≥ 85 Gy and in 8/62 (12.9 
%) for pts with a D90 HR-CTV < 85 Gy, respectively (p=0.055). 
Distant failures were seen in 1/47 (2.1 %) and in 16/62 (25.8 
%), respectively (p<0.001). This higher frequency of distant 
events in pts with a D90 HR-CTV < 85 Gy remained significant 
after exclusion of local failures: 0/44 (0 %) versus 11/54 (20.4 
%), respectively (p < 0.001). 
 
Conclusion: The inability to reach the target dose seems 
correlated with a higher propensity to metastases. Strategies 
integrating the metastatic risk are mandatory for maximizing 
the benefit of dose escalation. 
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Purpose or Objective: GEC-ESTRO recommendations for IGRT 
in brachytherapy, the incorporation of MRI in the planning 
and new MRI-compatible applicators have improved our 
treatments. But, in big tumours, intrauterine applicators 
don´t seem enough in order to reach a good coverage. 
Interstitial CT-MRI Utrecht (Elekta®) applicator with plastic 
needles lets improve HR-CTV and IR-CTV coverage sparing 
organs at risk. However, a further complication using 
interstitial applicators may be gynaecological bleeding during 
the withdrawal of the applicator.  
The purpose of this study is to review perioperative toxicity 
and dosimetry in patients with cervix tumours using 
interstitial CT-MRI Utrecht applicator. 
 
Material and Methods: Retrospective review of the records 
of 122 cervical cancer patients treated in our institution from 
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February´10 to September´15. To be included in the study, 
the treatment had to fulfill the criteria: (1) include a 
previous treatment of at least 45Gy of EBRT to the pelvis 
concomitant with cisplatin; (2) the BT boost consisted in 
insertion of interstitial Utrecht applicator under spinal 
anesthesia and individualized MRI planning. Each treatment 
was composed of 2 applications (7 days apart), with 2 
separated fractions (in 24 hours) of nominal 7 Gy (the aim is 
to obtain the HR-CTV and IR-CTV D90 higher than 85 and 65 
Gy EQD2 respectively keeping the OAR doses as low as 
possible with limits of D2cc of rectum and sigmoid lower than 
70 Gy EQD2 and 85 Gy EQD2 in case of bladder). Applicator 
withdrawal was performed at the surgical theatre. Toxicity 
score (gynaecological bleeding) were defined by CTCAE v4.0. 
 
Results: 110/122 (90.16%) patients were IIB stage or bigger, 
and in 68% of patients 6 needles were inserted in both 
applications. Median tumour volume at diagnoses was 39.8 cc 
(8.79-205) and median HR-CTV volume at first application 
was 18.01 cc (7.36-116.59). The final median biologically 
equivalent doses (EQD2) were D90 HR-CTV = 89.75 Gy10 
(78.50-94.00) and D90 IR-CTV = 67.90 Gy10 (58.60-77.40).  
For the first application, needles were used in all patients, 
and 4 (3.2%) patients required vaginal tamponade and/or 
stitch (Grade 2 CTCAE v4.0), and 2 (1.6%) patients required 
transfusion and/ or endoscopic intervention (Grade 3 CTCAE 
v4.0).  
For the second application, needles were used in 114 
patients, and 5 (4.3%) patients required vaginal tamponade 
and/or stitch (Grade 2 CTCAE v4.0) without bigger toxicities. 
 
Conclusion: Our results suggest that interstitial IGBT as 
recommended by the GEC-ESTRO, is a safe option without 
life-threatening consequences due to bleeding, and 
dosimetric results compare favorably with the traditional 
technique. 
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Purpose or Objective: MR-guided brachytherapy (MRgBT) 
improves local control and survival in patients with cervical 
cancer. It is expected that MRgBT will be standard of care 
within 5 years. MRgBT is more demanding of resources and 
optimized processes will be of great importance in assuring 
its widespread availability. Our aim was to determine the 
value of imaging and adaptive replanning prior to each MRgBT 
fraction compared to a less resource intensive approach 
tailored to specific technique considerations. 
 
Material and Methods: A total of 20 patients with cervical 
cancer who received external beam radiotherapy (EBRT: 45-
50.4 Gy in 1.8-2 Gy fractions) and high dose rate MRgBT (28 
Gy in 4 fractions using 2 insertions) were included in this 
study. A tandem/ring applicator (TR) was used in 9 patients, 
and a TR with interstitial needles in 4 patients for all 4 
fractions. In 3 of these 4 patients, further plan adaptation 
with increase in number of needles was performed for 
fractions 3 and 4. In the remaining 7 patients, a TR alone was 
used for fractions 1 and 2 and a TR plus needles for fractions 
3 and 4 to improve target coverage or OAR sparing. All 
patients underwent MR imaging, contouring and planning 
prior to each fraction. To simulate a more efficient approach 
with only one plan per insertion, optimized fraction 1 plan 
was applied to fraction 2 anatomy, and optimized fraction 3 
plan was applied to the fraction 4 anatomy. To assess value 
of plan adaptation, projected total dose from first insertion 
was compared to the final total dose following plan 
adaptation. 
 
Results: There was no systematic change in the high-risk 
clinical target volume (HRCTV) across fractions (mean range 
41-44 cm3). Mean cumulative HRCTVD90 with daily plan 
optimization was 92 Gy10, and the mean rectal, sigmoid and 
bladder D2cc doses were 67, 65 and 83 Gy3 respectively. 
There were no clinically significant changes in the mean 
HRCTV or OAR D2cc doses with only two plans prior to 
fractions 1 and 3. The GEC-ESTRO HRCTV target dose >85 
Gy10 was achieved in 16/20 patients with either daily plan 
optimization or planning only twice. All GEC-ESTRO OAR 
target doses (rectum <75 Gy3, sigmoid <75 Gy3, bladder <90 
Gy3) were achieved in 14/20 patients with optimized daily 
replanning, and this was maintained when only two plans 
were used. Plan adaptation with addition of interstitial 
needles for second insertion resulted in improved HRCTVD90 
dosimetry in 6/10 cases and in improved OAR dosimetry in 
4/10 cases. 
 
Conclusion: MRgBT can potentially improve outcomes of 
cervical cancer patients but is more resource intensive. This 
study suggests that improvements in efficiency can be 
achieved through process analysis and optimization. While 
adaptive MR-based replanning is fundamental to achieving 
the benefits of MRgBT, replanning at strategic intervals may 
be as effective as daily replanning with considerable savings 
in resources. 
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Purpose or Objective: To compare dosimetric plans using a 
commercially model based dose calculation algorithm 
(MBDCA) following TG186 recommendations, and the 
conventional TG43 method in an 192Ir high dose rate (HDR) 
gynaecological brachytherapy (BT) procedures using two 
types of cylindrical applicators. 
 
Material and Methods: We analyzed the data of six patients 
with cervical carcinoma, receiving a 192Ir HDR brachytherapy 
treatment. The dose was delivered with a micro-Selectron 
afterloader. A treatment plan was performed using both the 
TG43 and TG186 dose calculation methods of the Oncentra 
Brachy v4.5 treatment planning system (TPS). Two cylindrical 
applicators, of 30 mm and 35 mm diameter were used: the 
Vaginal Applicator Set and the Shielded Cylindrical Applicator 
Set, by Nucletron. The treatment dose is prescribed at 0.5 
cm distance from the cylinder wall (prescription point), with 
a treated extension of 3 cm. Analysis included dose volume 
histograms (DVH) for bladder and rectum and prescription 
point, according to American Brachytherapy Society (ABS) 
consensus guidelines (2012). The TG186 results were 
obtained using the standard accuracy level option of model-
based algorithm (Oncentra Brachy-Advanced Collapsed cone 
Engine (ACE), Elekta), resulting in calculation times on the 
order of 40 s. 
